国家医保局组织召开集采座谈会

Core Viewpoint - The National Healthcare Security Administration (NHSA) held discussions regarding the 11th batch of national drug procurement, emphasizing the importance of drug quality and supply assurance for selected enterprises [1]. Group 1: Meeting Outcomes - The NHSA organized three meetings on November 5-6, inviting representatives from the National Medical Products Administration, selected enterprises, experts, and media to discuss the drug procurement process [1]. - Selected enterprise leaders unanimously stated that drug quality is vital for their operations and committed to adhering to production quality management standards [1]. Group 2: Quality Control and Supply Assurance - Enterprises will implement a comprehensive quality control system throughout the drug lifecycle, ensuring compliance in production processes [1]. - There will be a focus on managing the use of raw materials, excipients, and packaging materials to maintain high-quality standards [1]. Group 3: Supply Chain Management - Companies are expected to arrange production capacity and inventory systematically to prepare for the execution of procurement results, particularly ensuring supply to grassroots and remote areas [1]. - The discussions also addressed concerns about preventing "involution" in project initiation, ensuring product quality, and optimizing procurement measures [1].